TY - JOUR
T1 - ECLIM-SEHOP
T2 - how to develop a platform to conduct academic trials for childhood cancer
AU - the Sociedad Española de Hematología y Oncología Pediátrica (SEHOP)
AU - Juan-Ribelles, Antonio
AU - Bautista, Francisco
AU - Cañete, Adela
AU - Rubio-San-Simón, Alba
AU - Alonso-Saladrigues, Anna
AU - Hladun, Raquel
AU - Rives, Susana
AU - Dapena, Jose Luís
AU - Fernández, Jose María
AU - Lassaletta, Álvaro
AU - Cruz, Ofelia
AU - Ramírez-Villar, Gemma
AU - Fuster, Jose Luís
AU - de Heredia, Cristina Diaz
AU - García-Ariza, Miguel
AU - Quiroga, Eduardo
AU - del Mar Andrés, María
AU - Verdú-Amorós, Jaime
AU - Molinés, Antonio
AU - Herrero, Blanca
AU - López, Mónica
AU - Márquez, Catalina
AU - Toboso, María
AU - Lendínez, Frencisco
AU - Sirvent, Jose Gómez
AU - Tallón, María
AU - Rodríguez, Guiomar
AU - Acha, Tomás
AU - Moreno, Lucas
AU - Fernández-Teijeiro, Ana
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/9
Y1 - 2024/9
N2 - Introduction: ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation. Methods: The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted. Results: ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months. Discussion: ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.
AB - Introduction: ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation. Methods: The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted. Results: ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months. Discussion: ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.
KW - Clinical research
KW - Clinical trials
KW - Drug development
KW - Metrics
KW - Pediatric hematology and oncology
UR - https://www.scopus.com/pages/publications/85189890722
U2 - 10.1007/s12094-024-03445-0
DO - 10.1007/s12094-024-03445-0
M3 - Article
C2 - 38600340
AN - SCOPUS:85189890722
SN - 1699-048X
VL - 26
SP - 2351
EP - 2359
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 9
ER -